Growth Metrics

Q32 Bio (QTTB) Cash from Financing Activities (2017 - 2026)

Q32 Bio's quarterly Cash from Financing Activities came in at $8.8 million in Q1 2026, up 663.19% quarter-over-quarter from -$1.6 million in Q4 2025.

Q32 Bio has reported Cash from Financing Activities for 10 years, with the latest figure at $8.8 million in Q1 2026.

  • For the quarter ending Q1 2026, Cash from Financing Activities changed N/A year-over-year to $8.8 million; the trailing twelve-month figure through Mar 2026 stood at $6.0 million (changed N/A YoY), and the FY2025 full-year result was -$3.1 million, down 103.28% from the prior year.
  • Cash from Financing Activities for Q1 2026 stood at $8.8 million, up from -$1.6 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $99.3 million in Q1 2024, with the low at -$5.5 million in Q2 2024.
  • Average Cash from Financing Activities over 5 years is $7.3 million, with a median of $100000.0 recorded in 2022.
  • Peak annual rise in Cash from Financing Activities reached 662206.67% in 2024, while the deepest fall reached 36913.33% in 2024.
  • Tracing QTTB's Cash from Financing Activities over 5 years: stood at $32000.0 in 2022, then soared by 137.5% to $76000.0 in 2023, then soared by 317.11% to $317000.0 in 2024, then slumped by 592.74% to -$1.6 million in 2025, then jumped by 663.19% to $8.8 million in 2026.
  • The last three Cash from Financing Activities figures came in at $8.8 million (Q1 2026), -$1.6 million (Q4 2025), and -$1.6 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 7.00 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -600,000.00
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 53,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -538.80 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -802.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 15.71 Mn
10 Q32 Bio 162.94 Mn 112.19 Mn - 8.80 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 8.80 Mn
Mar 31, 2026 8.80 Mn
Dec 31, 2025 -1.56 Mn
Dec 31, 2025 -1.56 Mn
Sep 30, 2025 -1.56 Mn
Sep 30, 2025 -1.56 Mn
Dec 31, 2024 317,000.00
Dec 31, 2024 317,000.00
Sep 30, 2024 997,000.00
Sep 30, 2024 997,000.00
Jun 30, 2024 -5.52 Mn
Jun 30, 2024 -5.52 Mn
Mar 31, 2024 99.35 Mn
Mar 31, 2024 99.35 Mn
Dec 31, 2023 76,000.00
Dec 31, 2023 76,000.00
Sep 30, 2023 300,000.00
Sep 30, 2023 300,000.00
Jun 30, 2023 15,000.00
Jun 30, 2023 15,000.00
Mar 31, 2023 15,000.00
Mar 31, 2023 15,000.00
Dec 31, 2022 32,000.00
Dec 31, 2022 32,000.00
Sep 30, 2022 124,000.00
Sep 30, 2022 124,000.00
Mar 31, 2022 440,000.00
Mar 31, 2022 440,000.00
Dec 31, 2021 1,000.00
Dec 31, 2021 1,000.00
Sep 30, 2021 379,000.00
Sep 30, 2021 379,000.00
Jun 30, 2021 49.75 Mn
Jun 30, 2021 49.75 Mn
Mar 31, 2021 2.04 Mn
Mar 31, 2021 2.04 Mn
Dec 31, 2020 52.00 Mn
Dec 31, 2020 52.00 Mn
Sep 30, 2020 410,000.00
Sep 30, 2020 410,000.00
Jun 30, 2020 241,000.00
Jun 30, 2020 241,000.00
Mar 31, 2020 447,000.00
Mar 31, 2020 447,000.00
Dec 31, 2019 22.58 Mn
Dec 31, 2019 22.58 Mn
Sep 30, 2019 614,000.00
Sep 30, 2019 614,000.00
Jun 30, 2019 134.70 Mn
Jun 30, 2019 134.70 Mn
Mar 31, 2019 325,000.00
Mar 31, 2019 325,000.00
Dec 31, 2018 41,000.00
Dec 31, 2018 41,000.00
Sep 30, 2018 25,000.00
Sep 30, 2018 25,000.00
Jun 30, 2018 151.89 Mn
Jun 30, 2018 151.89 Mn
Mar 31, 2018 -958,000.00
Mar 31, 2018 -958,000.00
Dec 31, 2017 11.66 Mn
Dec 31, 2017 11.66 Mn
Sep 30, 2017 83.09 Mn
Sep 30, 2017 83.09 Mn
Mar 31, 2017 20.48 Mn
Mar 31, 2017 20.48 Mn